man skjuler det man må vedrørende forskningen på CD 37. Resultatene blir pakket pent inn slik at konkurrentene ikke skal forstå hvor dette ender. Kursen blir lavere og lavere, jo bedre resultatene blir. Man finner da info fra andre på Internett, men gode børsmeldinger utblir. Man kan også legge merke til at det er lang mellom artiklene.

Om et par år er ser vi vel de store sigarene og smilefjesene. Man finner da noe nytt, som ikke kommer fra ledelsen.....................

Biotechnology Letters 2018 October 6

Anti-CD37 targeted immunotherapy of B-Cell malignancies

By : Zahra Payandeh, Effat Noori, Bahman Khalesi, Maysam Mard-Soltani, Jalal Abdolalizadeh, Saeed Khalili



CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.